Your browser doesn't support javascript.
Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective.
Saxena, Shailendra K; Kumar, Swatantra; Ansari, Saniya; Paweska, Janusz T; Maurya, Vimal K; Tripathi, Anil K; Abdel-Moneim, Ahmed S.
  • Saxena SK; Centre for Advanced Research (CFAR), Faculty of Medicine, King George's Medical University (KGMU), Lucknow, India.
  • Kumar S; The World Society for Virology (WSV), Al-Taif, Saudi Arabia.
  • Ansari S; The Indian Virological Society (IVS), New Delhi, India.
  • Paweska JT; Centre for Advanced Research (CFAR), Faculty of Medicine, King George's Medical University (KGMU), Lucknow, India.
  • Maurya VK; The World Society for Virology (WSV), Al-Taif, Saudi Arabia.
  • Tripathi AK; Centre for Advanced Research (CFAR), Faculty of Medicine, King George's Medical University (KGMU), Lucknow, India.
  • Abdel-Moneim AS; The World Society for Virology (WSV), Al-Taif, Saudi Arabia.
J Med Virol ; 94(4): 1738-1744, 2022 Apr.
Article in English | MEDLINE | ID: covidwho-1718408
ABSTRACT
As the latest identified novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern (VOC), the influence of Omicron on our globe grows promptly. Compared with the last VOC (Delta variant), more mutations were identified, which may address the characteristics of Omicron. Considering these crucial mutations and their implications including an increase in transmissibility, COVID-19 severity, and reduction of efficacy of currently available diagnostics, vaccines, and therapeutics, Omicron has been classified as one of the VOC. Notably, 15 of these mutations reside in the receptor-binding domain of spike glycoprotein, which may alter transmissibility, infectivity, neutralizing antibody escape, and vaccine breakthrough cases of COVID-19. Therefore, our present study characterizes the mutational hotspots of the Omicron variant in comparison with the Delta variant of SARS-CoV-2. Furthermore, detailed information was analyzed to characterize the global perspective of Omicron, including transmission dynamic, effect on testing, and immunity, which shall promote the progress of the clinical application and basic research. Collectively, our data suggest that due to continuous variation in the spike glycoprotein sequences, the use of coronavirus-specific attachment inhibitors may not be the current choice of therapy for emerging SARS-CoV-2 VOCs. Hence, we need to proceed with a sense of urgency in this matter.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 Type of study: Diagnostic study / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: J Med Virol Year: 2022 Document Type: Article Affiliation country: Jmv.27524

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 Type of study: Diagnostic study / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: J Med Virol Year: 2022 Document Type: Article Affiliation country: Jmv.27524